Abstract: The invention relates to an electrolyte solution suitable for use in a zinc-bromine battery, comprising zinc bromide and a mixture of at least two complexing agents selected from the group consisting of 1-R2-2-methyl pyridinium bromide and 1-R3-3-methyl pyridinium bromide salts, wherein each of R2 and R3 is independently an alkyl group having not less than five carbon atoms.

Abstract: The invention relates to a method of operating a zinc-bromine battery, especially at a high temperature, comprising adding 1-n-butyl-2-methyl-pyridinium bromide to the electrolyte of said battery, and charging or discharging said cell. Also provided is the use of 1-n-butyl-2-methyl-pyridinium bromide as an additive in a zinc-bromine battery operating at a temperature above 30° C., and an aqueous concentrate with high content of 1-n-butyl-2-methyl-pyridinium bromide.

Abstract: The invention relates to an electrolyte solution suitable for use in a zinc-bromine battery, comprising zinc bromide and a mixture of at least two complexing agents selected from the group consisting of 1-R2-2-methyl pyridinium bromide and 1-R3-3-methyl pyridinium bromide salts, wherein each of R2 and R3 is independently an alkyl group having not less than five carbon atoms.

Abstract: The invention relates to a method of operating a zinc-bromine battery, especially at a high temperature, comprising adding 1-n-butyl-2-methyl-pyridinium bromide to the electrolyte of said battery, and charging or discharging said cell. Also provided is the use of 1-n-butyl-2-methyl-pyridinium bromide as an additive in a zinc-bromine battery operating at a temperature above 30° C., and an aqueous concentrate with high content of 1-n-butyl-2-methyl-pyridinium bromide.

Abstract: A process for preparing an aqueous solution of N-ethyl-2-methylpyridinium bromide (2-MEPy), comprising reacting 2-picoline and ethyl bromide in a pressure reactor at a temperature above the melting point of the reaction mixture, combining the reaction product with water, wherein said reaction product consists essentially of 2-MEPy in a liquid form, and recovering an aqueous solution of 2-MEPy.

Abstract: A process for preparing an aqueous solution of N-ethyl-2-methylpyridinium bromide (2-MEPy), comprising reacting 2-picoline and ethyl bromide in a pressure reactor at a temperature above the melting point of the reaction mixture, combining the reaction product with water, wherein said reaction product consists essentially of 2-MEPy in a liquid form, and recovering an aqueous solution of 2-MEPy.

Abstract: The present invention provides new tyrphostin derivatives acting as protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, and/or which directly or indirectly affect proteins in the PTK-mediated signal transduction pathway, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Abstract: The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Abstract: The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.